CHRNA7 and schizophrenia: Because the α7 nAChR is required for supporting sensory gating abilities (Freedman et al., 1994), a cognitive ability that is reduced in the patients with schizophrenia, this receptor is considered a potential therapeutic target for diminishing sensory gating deficit in this disorder (Olincy and Stevens, 2007).